ReviewMolecular biology reports2025
Potential new drug sources for the treatment of Parkinson's disease: flavonoid O-glycosides.
Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Synthesis, Biological Evaluation, and Computational Studies of PhenolicMarine drugs · 2026Article
- Wogonin-mediated modulation of cellular signaling pathways: Mechanistic insights into neuroprotection.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease. With the increase in the global aging population, the global prevalence of PD has soared, and the burden of global medical resources is increasingly heavy. Although modern medicine has progressed in treating PD, existing drugs still have drawbacks regarding Mechanism and efficacy, intensifying the urgency of developing new drugs. Researchers have favored natural treatments for their safety in recent years and have increasingly become an essential source for developing new drugs. Flavonoid O-glycoside compounds are one of the main active ingredients of natural products and have shown satisfactory efficacy in treating PD, thus becoming potential drugs for treating neurodegenerative diseases. In this study, we systematically evaluated the Mechanism of several specific flavonoid O-glycoside compounds in the treatment of PD, conducted a relatively in-depth summary and discussion of their biological activities, and compared them with other flavonoid O-glycoside compounds. This provides a theoretical basis for further future mechanism research on flavonoid O-glycoside compounds. And lay the foundation and set an example for the development and application of natural products. This review indicates that flavonoid O-glycoside compounds are up-and-coming new therapeutic drugs for Parkinson's disease (PD) and can be used in PD prevention and treatment strategies.
Indexed as
Identifiers
41023471What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.